Pfizer Tries Injecting New Life Into Its Strategy With A Generic Injectables Unit
This article was originally published in The Pink Sheet Daily
Executive Summary
Entering the sterile injectables business is one step in Pfizer's efforts to buttress its mature products by diversifying into niche markets.
You may also be interested in...
Pfizer's Message To Wall Street: We're Doing Things Differently Now
Exubera's failure was a defining moment for CEO Jeff Kindler, who says the episode motivated him to transform the way Pfizer makes decisions.
Pfizer's Message To Wall Street: We're Doing Things Differently Now
Exubera's failure was a defining moment for CEO Jeff Kindler, who says the episode motivated him to transform the way Pfizer makes decisions.
Pfizer Thinks Small: Partnership With Protalix On Gaucher Drug Eyes Cheaper Plant-Based Production
Pfizer's licensing deal with Protalix for global rights to the enzyme replacement therapy taliglucerase for the treatment of Gaucher disease, announced Dec. 1, signals the drug giant's interest in the orphan drug space. It also plays into the company's biosimilar strategy, given that taliglucerase will likely be positioned as a lower-cost alternative to Genzyme's Cerezyme (imiglucerase)